Optimal duration of anticoagulation after venous thromboembolism

Circulation

Volumn 123, Issue 6, 2011, Pages 664-667

  Goldhaber, Samuel Z ^a   Piazza, Gregory ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anticoagulants; deep vein thrombosis; pulmonary embolism; thromboembolism

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ENOXAPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; CELLULITIS; DEEP VEIN THROMBOSIS; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; ILIOFEMORAL VEIN THROMBOSIS; INTERNATIONAL NORMALIZED RATIO; LEG SWELLING; LUNG EMBOLISM; NEOPLASM; PHYSICIAN; PRIORITY JOURNAL; RECANALIZATION; RECURRENT DISEASE; RISK FACTOR; STREPTOCOCCAL PHARYNGITIS; THORAX RADIOGRAPHY; TREATMENT DURATION; ULTRASOUND; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGED; ALTITUDE SICKNESS; ANTICOAGULANTS; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; ENOXAPARIN; FEMALE; HUMANS; MALE; NEOPLASMS; POPLITEAL VEIN; PULMONARY EMBOLISM; RISK FACTORS; SEX FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 79951588562     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.970822     Document Type: Article

References (21)

1. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009; 29:298-310.
2. Nijkeuter M, Sohne M, Tick LW, Kamphuisen PW, Kramer MH, Laterveer L, van Houten AA, Kruip MJ, Leebeek FW, Buller HR, Huisman MV. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest. 2007;131:517-523. (Pubitemid 46280414)
3. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350: 2558-2563.
4. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678-1683.
5. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609-1614. (Pubitemid 46648646)
6. Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164:92-96. (Pubitemid 38067394)
7. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna Prediction Model. Circulation. 2010;121:1630-1636.
8. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160: 761-768. (Pubitemid 30165236)
9. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
10. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.
11. White RH, Zhou H, Murin S. Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idio-pathic pulmonary embolism. Thromb Haemost. 2008;99:683-690. (Pubitemid 351694224)
12. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagu-lation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706-715. (Pubitemid 41159290)
13. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639. (Pubitemid 36975995)
14. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434. (Pubitemid 36407171)
15. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721. (Pubitemid 37315008)
16. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scan-napieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009;150:577-585.
17. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-1789. (Pubitemid 44631361)
18. Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009;7: 611-618.
19. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Mar-chiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboem-bolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100:3484-3488. (Pubitemid 35303914)
20. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous throm-boembolism in patients with cancer. N Engl J Med. 2003;349:146-153. (Pubitemid 36818784)
21. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S-545S.